Akebia Therapeutics, Inc.
AKBA
$1.59
$0.020.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.93% | 8.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.93% | 8.96% | |||
| Cost of Revenue | -4.07% | 31.26% | |||
| Gross Profit | -6.32% | 5.25% | |||
| SG&A Expenses | 9.56% | 3.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.50% | 10.59% | |||
| Operating Income | -68.64% | 3.74% | |||
| Income Before Tax | 367.61% | -95.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 118.62% | -95.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 118.62% | -95.96% | |||
| EBIT | -68.64% | 3.74% | |||
| EBITDA | -67.14% | 3.67% | |||
| EPS Basic | 122.22% | -96.54% | |||
| Normalized Basic EPS | 237.50% | -95.21% | |||
| EPS Diluted | 122.22% | -96.54% | |||
| Normalized Diluted EPS | 225.00% | -95.06% | |||
| Average Basic Shares Outstanding | 0.85% | 11.49% | |||
| Average Diluted Shares Outstanding | 1.21% | 12.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||